Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Structure of Summit deal is beneficial to Sarepta, Wedbush believes

Tuesday, October 4, 2016 13:09
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Sarepta Therapeutics Inc’s (NASDAQ:SRPT) deal with the UK’s Summit Therapeutics (NASDAQ:SMMT) is a low-risk/high-reward option for the US company, according to Wedbush Securities.

Sarepta will contribute to the development of Summit’s potentially breakthrough treatment for Duchenne muscular dystrophy (DMD), a muscle wasting disease that affects boys, in return for European rights and a Latin America option.

Summit is testing two formulations of its lead candidate ezutromid in the proof of concept study.

Ezutromid is a utrophin modulator and acts as a potential disease-modifying treatment for all patients regardless of their underlying dystrophin gene mutation.

“Its proof-of-concept study is open label with MRI as a primary endpoint; muscle biopsy data at 24 weeks are expected in 2Q/3Q 2017. A placebo controlled study is slated to begin later next year. Beyond ezutromid, Summit is working with its Oxford collaborators on next-generation utrophin modulators; Sarepta has rights to both ezutromid and its pipeline,” Wedbush noted.

Sarepta will pay a US$40mln up-front fee to Summit. It will also pay a clinical milestone of US$22mln when the last patient is dosed in ‘PhaseOut DMD’. The phase II trial of ezutromid, on or after April 2017 with the potential for an additional US$20mln in development milestones for ezutromid and US$65mln for the pipeline, US$150mln in regulatory milestones for ezutromid and US$225mln for its pipeline with US$330mln in sales milestones by product.

After December 2017, Sarepta will contribute 45% to research & development costs with a committed minimum spend prior to the end of 2019.

“In our view, this deal structure is beneficial to Sarepta, with a commitment to development only after proof-of-concept data are obtained,” Wedbush said.

The broker reiterated its ‘outperform’ rating and US$66 price target for Sarepta.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.